May 2022 - an apology, international drug bulletins, mirtazapine and oral antivirals for covid-19

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the May 2022 issue of DTB. They talk about drug bulletins across the world and the role of the International Society of Drug Bulletins in supporting bulletins and ensuring that they are intellectually and financially independent (https://dtb.bmj.com/content/60/5/66). They review a study that assessed the use of mirtazapine for treating agitation in people with dementia (https://dtb.bmj.com/content/60/5/68). The editors also discuss the evidence behind two new oral antivirals that have been licensed for the treatment of covid-19 (https://dtb.bmj.com/content/60/5/73).

Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.